ArticleLeukemia2020
Efficient treatment of murine acute GvHD by in vitro expanded donor regulatory T cells.
Article in Leukemia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 56 citations in OpenAlex.
- FOXP-stabilization of thebioRxiv : the preprint server for biology · 2026Article
- Review
- Engineered CD40-biosensor-expressing Treg cells as a cell therapy approach for inflammatory diseases.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Automated GMP-compatible production of universal CAR Tregs for organ-targeted tolerance induction.Journal of translational medicine · 2025Article
- Immunological mechanisms underlying the novel application of mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) in graft-versus-host disease (GvHD) therapy.Molecular biology reports · 2025Review
- Nanographene Oxide Attenuates Acute GVHD by Modulating Macrophage Polarization in a Xenogeneic Mouse Model.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Tissue-adapted Tregs harness inflammatory signals to promote intestinal repair from therapy-related injury.Signal transduction and targeted therapy · 2025Article
- HLA matching or CRISPR editing of HLA class I/II enables engraftment and effective function of allogeneic human regulatory T cell therapy in a humanized mouse transplantation model.Nature communications · 2025Article
- Novel Autologous Regulatory T-Cell Therapy Ameliorates DSS-Induced Colitis in Humanized Mice.Inflammatory bowel diseases · 2025Article
- Cellular therapies for the prevention and treatment of acute graft-versus-host disease.Stem cells (Dayton, Ohio) · 2025Review
- Mendelian randomization analysis of blood metabolites and immune cell mediators in relation to GVHD and relapse.BMC medicine · 2025Article
- Improving bench-to-bedside translation for acute graft-versus-host disease models.Disease models & mechanisms · 2025Review
- Flow Cytometry Analysis of Graft Conditioning on the T-Cell Response in Graft-Versus-Host Disease Following Murine Allogeneic Transplantation.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Graft-Versus-Host Disease Mouse Models: A Clinical-Translational Perspective.Methods in molecular biology (Clifton, N.J.) · 2025Review
- Cell Therapy as a Way to Increase the Effectiveness of Hematopoietic Stem Cell Transplantation.Cells · 2024Review
- Donor regulatory T cells rapidly adapt to recipient tissues to control murine acute graft-versus-host disease.Nature communications · 2024Article
- Cord blood T regulatory cells synergize with ruxolitinib to improve GVHD outcomes.Frontiers in transplantation · 2024Article
- Article
- Regulatory T cells in lung disease and transplantation.Bioscience reports · 2023Review
- Graft conditioning with fluticasone propionate reduces graft-versus-host disease upon allogeneic hematopoietic cell transplantation in mice.EMBO molecular medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute graft-versus-host disease (aGvHD) is a frequent complication after allogeneic bone marrow/stem cell transplantation (BMT/SCT) induced by co-transplanted alloreactive conventional donor T cells. We previously demonstrated that the adoptive transfer of donor CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.